(a) Name of Issuer: Autolus Therapeutics plc
(b) Address of Issuer’s principal executive offices: The Mediaworks, 191 Wood Lane, London W12 7FP, United Kingdom
(a) | Name of reporting persons filing: |
| (i) | Syncona Portfolio Limited; |
| (ii) | Syncona Holdings Limited; |
| (iii) | Syncona Investment Management Limited; |
| (vi) | Christopher Hollowood |
(b) | Address of principal business office or, if none, residence: |
The address of the principal business office of Syncona Portfolio Limited, Syncona Holdings Limited and Syncona Limited is Frances House, PO Box 273, Sir William Place, St. Peter Port, Guernsey, GY1 3RD, Channel Islands. The address of the principal business office of Syncona Investment Management Limited, Roel Bulthuis and Christopher Hollowood is 2nd Floor, 8 Bloomsbury Street, London WC1B 3SR, United Kingdom.
Syncona Portfolio Limited, Syncona Holdings Limited and Syncona Limited’s citizenship is Guernsey. Syncona Investment Management Limited and Christopher Hollowood’s citizenship is United Kingdom. Roel Bulthuis’ citizenship is the Netherlands.
(d) | Title and class of securities: |
Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares (“ADS”). Each ADS represents one ordinary share, nominal value $0.000042 per share, of the Issuer.
There is no CUSIP number assigned to the ordinary shares. CUSIP number 05280R 100 has been assigned to the ADS, which are quoted on the Nasdaq Global Select Market under the symbol “AUTL.”
Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
Not applicable.
The following information with respect to the ownership of Ordinary Shares of the Issuer by the Reporting Persons filing this statement on Schedule 13G/A is provided as of December 31, 2023:
Page 8 of 11